ENTADFI
Peakfinasteride; tadalafil
NDAORALCAPSULE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ENTADFI (finasteride; tadalafil) is tadalafil. First approved in 2021.
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENTADFI is a fixed-dose oral combination of finasteride (a Type II 5α-reductase inhibitor) and tadalafil (a PDE5 inhibitor) approved for benign prostatic hyperplasia (BPH) symptoms in men. Finasteride reduces DHT-driven prostate enlargement through enzyme inhibition, while tadalafil improves smooth muscle relaxation in the prostate and bladder via PDE5 selectivity. The combination addresses both mechanical obstruction and functional symptoms of BPH.
Peak
Product is in peak commercial phase with moderate competitive pressure (30 rating), indicating active promotional spend and stable field team investment.
Mechanism of Action
tadalafil. Finasteride: The development and enlargement of the prostate gland is dependent on the potent androgen, 5α-dihydrotestosterone (DHT). Type II 5α-reductase metabolizes testosterone to DHT in the prostate gland, liver and skin. DHT induces androgenic effects by binding to androgen…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.